- Home
- AURE vs ATHA Comparison
AURE vs ATHA Comparison
Compare AURE & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AURE
- ATHA
- Stock Information
- Founded
- AURE 2018
- ATHA 2011
- Country
- AURE Hong Kong
- ATHA United States
- Employees
- AURE N/A
- ATHA N/A
- Industry
- AURE Finance: Consumer Services
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- AURE Finance
- ATHA Health Care
- Exchange
- AURE Nasdaq
- ATHA Nasdaq
- Market Cap
- AURE 19.4M
- ATHA 16.8M
- IPO Year
- AURE N/A
- ATHA 2020
- Fundamental
- Price
- AURE $0.42
- ATHA $4.08
- Analyst Decision
- AURE
- ATHA
- Analyst Count
- AURE 0
- ATHA 0
- Target Price
- AURE N/A
- ATHA N/A
- AVG Volume (30 Days)
- AURE 3.1M
- ATHA 31.7K
- Earning Date
- AURE 02-13-2026
- ATHA 11-07-2025
- Dividend Yield
- AURE N/A
- ATHA N/A
- EPS Growth
- AURE N/A
- ATHA N/A
- EPS
- AURE N/A
- ATHA N/A
- Revenue
- AURE $142,570.00
- ATHA N/A
- Revenue This Year
- AURE N/A
- ATHA N/A
- Revenue Next Year
- AURE N/A
- ATHA N/A
- P/E Ratio
- AURE N/A
- ATHA N/A
- Revenue Growth
- AURE N/A
- ATHA N/A
- 52 Week Low
- AURE $0.31
- ATHA $2.20
- 52 Week High
- AURE $2.70
- ATHA $8.26
- Technical
- Relative Strength Index (RSI)
- AURE N/A
- ATHA 62.29
- Support Level
- AURE N/A
- ATHA $3.78
- Resistance Level
- AURE N/A
- ATHA $4.23
- Average True Range (ATR)
- AURE 0.00
- ATHA 0.24
- MACD
- AURE 0.00
- ATHA -0.06
- Stochastic Oscillator
- AURE 0.00
- ATHA 67.91
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.